(Q24188267)

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Dronabinol and chronic pain: importance of mechanistic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia syndrome. General principles and coordination of clinical care and patient education

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

The dilemma of medical marijuana use by rheumatology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

The endocannabinoid system and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia syndrome: a somatoform disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Review of pharmacological therapies in fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Medicinal use of cannabis: history and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Drugs for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Candidate gene studies of fibromyalgia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Amygdala activity contributes to the dissociative effect of cannabis on pain perception

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Duloxetine use in chronic painful conditions--individual patient data responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

The endocannabinoid system as an emerging target of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Worldwide epidemiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Etiology and pathophysiology of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Pregabalin in fibromyalgia--responder analysis from individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

What is fibromyalgia, how is it diagnosed, and what does it really mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Fibromyalgia research criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Systematic review with meta-analysis: cytokines in fibromyalgia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Small fibre pathology in patients with fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Anticonvulsants for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

Antiepileptic drugs for neuropathic pain and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

inferred from DOI database lookup

7 January 2021

based on heuristic

[Influence of depression on fibromyalgia : A systematic review]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694

inferred from DOI database lookup

7 January 2021

based on heuristic

Patient-centered perspective on treatment outcomes in chronic pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694